Join host, Carmel Fisher for an exclusive conversation with Christopher Schaber, CEO of Soligenix Inc. (NASDAQ: SNGX), as we explore the company’s exciting clinical developments in rare disease therapeutics.
With positive interim results from their extended HyBryte™ treatment study and enrollment now open for both their confirmatory Phase 3 CTCL trial and Phase 2 Behçet’s Disease study, Soligenix is advancing multiple promising programs simultaneously.
Schaber discusses the clinical differentiation of HyBryte™, which continues showing improvement even after treatment stops, the company’s international expansion strategy through their new European Medical Advisory Board, and how they’re navigating funding challenges in an uncertain regulatory environment.
Discover what makes Soligenix’s approach unique in the rare disease landscape and the key milestones investors should watch for in 2025.
Disclaimer:
The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.
Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions. Past performance is not indicative of future results.
The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.
By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.
Always do your own due diligence and invest responsibly.
